Chwilio Deddfwriaeth

Commission Delegated Regulation (EU) 2016/161Dangos y teitl llawn

Commission Delegated Regulation (EU) 2016/161 of 2 October 2015 supplementing Directive 2001/83/EC of the European Parliament and of the Council by laying down detailed rules for the safety features appearing on the packaging of medicinal products for human use (Text with EEA relevance)

 Help about what version

Pa Fersiwn

 Help about opening options

Dewisiadau AgorExpand opening options

 Help about UK-EU Regulation

Deddfwriaeth yn deillio o’r UE

Pan adawodd y DU yr UE, cyhoeddodd legislation.gov.uk ddeddfwriaeth yr UE a gyhoeddwyd gan yr UE hyd at ddiwrnod cwblhau’r cyfnod gweithredu (31 Rhagfyr 2020 11.00 p.m.). Ar legislation.gov.uk, mae'r eitemau hyn o ddeddfwriaeth yn cael eu diweddaru'n gyson ag unrhyw ddiwygiadau a wnaed gan y DU ers hynny.

Status:

EU_status_warning_original_version
This legislation may since have been updated - see the latest available (revised) version

CHAPTER X LISTS OF DEROGATIONS AND NOTIFICATIONS TO THE COMMISSION

Article 45Lists of derogations from bearing or not bearing the safety features

1.The list of medicinal products or product categories subject to prescription which shall not bear the safety features are set out in Annex I to this Regulation.

2.The list of medicinal products or product categories not subject to prescription which shall bear the safety features are set out in Annex II to this Regulation.

Article 46Notifications to the Commission

1.National competent authorities shall notify the Commission of non-prescription medicinal products which they judge to be at risk of falsification as soon as they become aware of such risk. For that purpose, they shall use the form set out in Annex III to this Regulation.

2.National competent authorities may inform the Commission of medicinal products which they deem not to be at risk of falsification. For that purpose, they shall use the form set out in Annex IV to this Regulation.

3.For the purposes of the notifications referred to in paragraphs 1 and 2, national competent authorities shall conduct an assessment of the risks of and arising from falsification of such products taking into account the criteria listed in Article 54a(2)(b) of Directive 2001/83/EC.

4.When submitting to the Commission the notification referred to in paragraph 1, national competent authorities shall provide the Commission with evidence and documentation supporting the presence of incidents of falsification.

Article 47Evaluation of the notifications

Where, following a notification as referred to in Article 46, the Commission or a Member State considers, on the basis of casualties or hospitalisations of citizens of the Union due to exposure to falsified medicinal products, that rapid action is required to protect public health, the Commission shall asses the notification without delay and at the latest within 45 days.

Yn ôl i’r brig

Options/Help